Role of IRF4 in resistance to immunomodulatory (IMid) compounds(®) in Waldenström’s macroglobulinemia

BACKGROUND: Immunomodulatory drugs, IMid compounds, are active in Waldenström's macroglobulinemia (WM), although in a lesser extent than multiple myeloma, where it was initially developed. We hypothesized WM tumour cells might develop mechanisms of resistance, and sought to identify and describ...

Descripción completa

Detalles Bibliográficos
Autores principales: Bertrand, Elisabeth, Jouy, Nathalie, Manier, Salomon, Fouquet, Guillemette, Guidez, Stéphanie, Boyle, Eileen, Noel, Stéphanie, Tomowiak, Cécile, Herbaux, Charles, Schraen, Susanna, Preudhomme, Claude, Quesnel, Bruno, Poulain, Stéphanie, Leleu, Xavier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762562/
https://www.ncbi.nlm.nih.gov/pubmed/29348877
http://dx.doi.org/10.18632/oncotarget.22872

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762562/
https://www.ncbi.nlm.nih.gov/pubmed/29348877
http://dx.doi.org/10.18632/oncotarget.22872

Ejemplares similares